drugset / Trial / NCT00152048

Evaluation of Eflornithine on Facial and Forearm Skin

NCT00152048

Phase 4 Completed 78 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate whether regular use of eflornithine 11.5% cream in treating women with facial hair will induce skin damage (atrophy) on the face and/or forearms

Timeline

Start
2004-11-30
Primary completion
Completion
2005-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Eflornithine Small molecule 11.5 % Topical

Indications